T. Sourjina

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

Martin R. Stockler, Vernon Harvey, Prudence A. Francis et al. · Journal of Clinical Oncology · 2011 · 152 citations · Full text

Medicine, Oncology, Pharmacology +14

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial

Niall C. Tebbutt, Michelle M. Cummins, T. Sourjina et al. · British Journal of Cancer · 2010 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17

A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC)

Martin R. Stockler, T. Sourjina, Peter Grimison et al. · Journal of Clinical Oncology · 2007 · 59 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

ATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer—Final results of a multicentre phase II trial by the AGITG

N. C. Tebbutt, T. Sourjina, A. H. Strickland et al. · Journal of Clinical Oncology · 2008 · 27 citations

Medicine, Oncology, Pharmacology +17

Comparing patients’ and clinicians’ assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial)

Michaella Jayne Smith, P. Grantley Gill, Neil Wetzig et al. · Breast Cancer Research and Treatment · 2008 · 19 citations

Medicine, Oncology, Surgery +16